The comparison of levofloxacin- and clarithromycin-based bismuth quadruple therapy regimens in Helicobacter pylori eradication
Objective: The aim of the current study was to compare the efficacy of quadruple therapy including levofloxacin and clarithromycin for Helicobacter pylori eradication. Methods: This clinical trial study was conducted on 189 patients with H. pylori infection who underwent gastroscopy and stomach biop...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2020-01-01
|
Series: | Journal of Research in Pharmacy Practice |
Subjects: | |
Online Access: | http://www.jrpp.net/article.asp?issn=2319-9644;year=2020;volume=9;issue=2;spage=101;epage=105;aulast=Arj |
id |
doaj-5d2bcf97be3d4b3b9638d13ac86e6bab |
---|---|
record_format |
Article |
spelling |
doaj-5d2bcf97be3d4b3b9638d13ac86e6bab2020-11-25T02:38:10ZengWolters Kluwer Medknow PublicationsJournal of Research in Pharmacy Practice2319-96442279-042X2020-01-019210110510.4103/jrpp.JRPP_19_86The comparison of levofloxacin- and clarithromycin-based bismuth quadruple therapy regimens in Helicobacter pylori eradicationAbbas ArjMarzieh MollaeiMohsen RazavizadehAlireza MoravejiObjective: The aim of the current study was to compare the efficacy of quadruple therapy including levofloxacin and clarithromycin for Helicobacter pylori eradication. Methods: This clinical trial study was conducted on 189 patients with H. pylori infection who underwent gastroscopy and stomach biopsy in Shahid Beheshti Hospital, Kashan, Iran. After classification of patients, one group was treated with bismuth subcitrate (120 mg, 2 tablet/12 h), omeprazole (20 mg/12 h), amoxicillin (1 g/12 h), and clarithromycin (500 mg/12 h) and other group with bismuth subcitrate (120 mg, 2 tablet/12 h), omeprazole (20 mg/12h), amoxicillin (1 g/12 h), and levofloxacin (500 mg/12 h) for 2 weeks. After the end of the antibiotic treatment, omeprazole therapy was continued for 4 weeks. Two weeks after discontinuation of omeprazole, fecal antigen test was performed for both the groups to confirm the eradication of H. pylori infection. Findings: The success of H. pylori eradication in the levofloxacin and clarithromycin groups was observed in 78 (89.7%) and 71 (69.6%) patients, respectively (P < 0.01). A significant difference was also seen between the two groups in terms of side effects and its incidence (P < 0.01), so that the incidence of side effect types in the clarithromycin group was more than the levofloxacin group except muscular pain and fatigue (P < 0.01). Conclusion: Levofloxacin-based quadruple regimen therapy was superior to clarithromycin-based quadruple regimens regarding H. pylori eradication and side effects. Therefore, the levofloxacin-based regimen can be considered as an effective treatment for the first-line anti-H. pylori therapy.http://www.jrpp.net/article.asp?issn=2319-9644;year=2020;volume=9;issue=2;spage=101;epage=105;aulast=Arjclarithromycin therapyhelicobacter pylori infectionlevofloxacin |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Abbas Arj Marzieh Mollaei Mohsen Razavizadeh Alireza Moraveji |
spellingShingle |
Abbas Arj Marzieh Mollaei Mohsen Razavizadeh Alireza Moraveji The comparison of levofloxacin- and clarithromycin-based bismuth quadruple therapy regimens in Helicobacter pylori eradication Journal of Research in Pharmacy Practice clarithromycin therapy helicobacter pylori infection levofloxacin |
author_facet |
Abbas Arj Marzieh Mollaei Mohsen Razavizadeh Alireza Moraveji |
author_sort |
Abbas Arj |
title |
The comparison of levofloxacin- and clarithromycin-based bismuth quadruple therapy regimens in Helicobacter pylori eradication |
title_short |
The comparison of levofloxacin- and clarithromycin-based bismuth quadruple therapy regimens in Helicobacter pylori eradication |
title_full |
The comparison of levofloxacin- and clarithromycin-based bismuth quadruple therapy regimens in Helicobacter pylori eradication |
title_fullStr |
The comparison of levofloxacin- and clarithromycin-based bismuth quadruple therapy regimens in Helicobacter pylori eradication |
title_full_unstemmed |
The comparison of levofloxacin- and clarithromycin-based bismuth quadruple therapy regimens in Helicobacter pylori eradication |
title_sort |
comparison of levofloxacin- and clarithromycin-based bismuth quadruple therapy regimens in helicobacter pylori eradication |
publisher |
Wolters Kluwer Medknow Publications |
series |
Journal of Research in Pharmacy Practice |
issn |
2319-9644 2279-042X |
publishDate |
2020-01-01 |
description |
Objective: The aim of the current study was to compare the efficacy of quadruple therapy including levofloxacin and clarithromycin for Helicobacter pylori eradication. Methods: This clinical trial study was conducted on 189 patients with H. pylori infection who underwent gastroscopy and stomach biopsy in Shahid Beheshti Hospital, Kashan, Iran. After classification of patients, one group was treated with bismuth subcitrate (120 mg, 2 tablet/12 h), omeprazole (20 mg/12 h), amoxicillin (1 g/12 h), and clarithromycin (500 mg/12 h) and other group with bismuth subcitrate (120 mg, 2 tablet/12 h), omeprazole (20 mg/12h), amoxicillin (1 g/12 h), and levofloxacin (500 mg/12 h) for 2 weeks. After the end of the antibiotic treatment, omeprazole therapy was continued for 4 weeks. Two weeks after discontinuation of omeprazole, fecal antigen test was performed for both the groups to confirm the eradication of H. pylori infection. Findings: The success of H. pylori eradication in the levofloxacin and clarithromycin groups was observed in 78 (89.7%) and 71 (69.6%) patients, respectively (P < 0.01). A significant difference was also seen between the two groups in terms of side effects and its incidence (P < 0.01), so that the incidence of side effect types in the clarithromycin group was more than the levofloxacin group except muscular pain and fatigue (P < 0.01). Conclusion: Levofloxacin-based quadruple regimen therapy was superior to clarithromycin-based quadruple regimens regarding H. pylori eradication and side effects. Therefore, the levofloxacin-based regimen can be considered as an effective treatment for the first-line anti-H. pylori therapy. |
topic |
clarithromycin therapy helicobacter pylori infection levofloxacin |
url |
http://www.jrpp.net/article.asp?issn=2319-9644;year=2020;volume=9;issue=2;spage=101;epage=105;aulast=Arj |
work_keys_str_mv |
AT abbasarj thecomparisonoflevofloxacinandclarithromycinbasedbismuthquadrupletherapyregimensinhelicobacterpylorieradication AT marziehmollaei thecomparisonoflevofloxacinandclarithromycinbasedbismuthquadrupletherapyregimensinhelicobacterpylorieradication AT mohsenrazavizadeh thecomparisonoflevofloxacinandclarithromycinbasedbismuthquadrupletherapyregimensinhelicobacterpylorieradication AT alirezamoraveji thecomparisonoflevofloxacinandclarithromycinbasedbismuthquadrupletherapyregimensinhelicobacterpylorieradication AT abbasarj comparisonoflevofloxacinandclarithromycinbasedbismuthquadrupletherapyregimensinhelicobacterpylorieradication AT marziehmollaei comparisonoflevofloxacinandclarithromycinbasedbismuthquadrupletherapyregimensinhelicobacterpylorieradication AT mohsenrazavizadeh comparisonoflevofloxacinandclarithromycinbasedbismuthquadrupletherapyregimensinhelicobacterpylorieradication AT alirezamoraveji comparisonoflevofloxacinandclarithromycinbasedbismuthquadrupletherapyregimensinhelicobacterpylorieradication |
_version_ |
1724792373687353344 |